Association found between industry funding and promotional pieces on menopausal hormone therapy

Mar 15, 2011

There may be a link between receiving industry funding for speaking, consulting, or research, and the publication of apparently promotional opinion pieces on menopausal hormone therapy. Furthermore, such publications may encourage physicians to continue prescribing these therapies to women of menopausal age. These are the key findings of a study by Adriane Fugh-Berman from Georgetown University Medical Center, Washington D.C., USA, and colleagues, published in this week's PLoS Medicine.

Over the past three decades, menopausal hormones have been heavily promoted for preventing disease in women. However, the 2004 federally-funded Women's Health Initiative study that enrolled more than 26,000 women in the USA found that the most popular estrogen-progestin and estrogen-only formulations (often prescribed to women around the age of menopause) increased the risk of stroke, deep vein thrombosis, , and incontinence; the combined therapy also increased risk. Two years after the results of the Women's Health Initiative were published, a survey of more than 700 practicing gynecologists—the specialists who prescribe the majority of hormone replacement therapies—in the USA found that almost half did not find the findings of the Women Health Initiative Study convincing. This current study investigated whether promotional tone could be identified in narrative review articles regarding .

The authors conducted a comprehensive literature search that identified 340 relevant articles published between July 2002 and June 2006—the 4 years following the cessation of the estrogen-progestin arm of the Women's health Initiative study. Ten authors had published 4-6 articles, 47 had published 2-3 articles, and 371 had published one article each. The researchers focused on authors who had published four or more articles in the four-year period under study. After author names and affiliations were removed, 50 articles were independently evaluated by three readers for scientific accuracy and for tone.

Although most of the articles were scientifically accurate, common themes in the 50 articles included arguments that clinical trial results should not guide treatment for individuals, and suggestions that the risks associated with hormone therapy have been exaggerated and that the benefits of hormone therapy have been, or will be, proven. Of the ten authors studied, eight were found to have received payment for speaking or consulting on behalf of menopause hormone manufacturers and 30 of 32 articles evaluated as promoting hormone therapy were written by those with such potential financial conflicts of interest. Articles promoting the use of menopausal hormone therapy were more than twice as likely to have been written by authors with potential conflicts of interest as by authors without such conflicts of interest.

The authors say: "There may be a connection between industry funding for research, speaking, or consulting and the publication of promotional pieces on menopausal ." They add: ''Health care providers should exercise caution if they choose to read such articles."

Explore further: Amgen misses 1Q views as higher costs cut profit

More information: Fugh-Berman A, McDonald CP, Bell AM, Bethards EC, Scialli AR (2011) Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles. PLoS Med 8(3): e1000425. doi:10.1371/journal.pmed.1000425

add to favorites email to friend print save as pdf

Related Stories

Menopausal hormone therapy may increase risk of ovarian cancer

Nov 09, 2010

Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention ...

Hormone therapy raises cancer risk

Jan 16, 2008

Menopausal women who take hormone combinations for their symptoms are more likely to get an uncommon type of breast cancer much earlier than experts believed.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

22 hours ago

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Elissa
not rated yet Mar 16, 2011
I use Hormonal Therapy and it has been a GREAT help. Not only for the common & usual symptoms of menopause, but of great improvement in Mental Health. Now, my insurance wants to eliminate their monatary contribution for Hormonal Therapy. WHY? Do they think that because this has been going on since Eve, Hormonal Therapy is not of consequence? Well, it is. I believe if Hormone levels were checked in people with mental illness, in their 20's, possibly younger or at any age and imbalances were found,it's very possible Hormonal Therapy would help. I wish my hormone levels were checked when I was in my 20's,because it may have made a vast difference in my mental health. Diagnosed with severe depression which I get disability for. I have struggled and worked hard to get my mental health back in order and Hormonal Therapy did a great deal for me, in that aspect--not to mention the wonders it did for me going thru menopause. Age -54.

More news stories

Cyber buddy is better than 'no buddy'

A Michigan State University researcher is looking to give exercise enthusiasts the extra nudge they need during a workout, and her latest research shows that a cyber buddy can help.

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...